Replies to post #1400 on SurModics Inc (SRDX)

[Democritus_of_Abdera]

Dew, I wonder what slow release formulation of JSM 6427 Jerini Ophthalmic is planning to use “To address patient convenience as well as compliance”... for treatment of ARMD.

In the presentations that I have seen, Jerini has used mini-osmotic pumps to infuse JSM6427 over prolonged periods. i.e.:

Dietrich T, Onderka J, Bock, F, Hos D, Zahn G, Stragies R, Kruse FE, Cursiefen C (2007). Effect of Integrin Alpha 5 Inhibition on Lymphangiogeneis and Recruitment of CD11b-Positive Macrophages in a Murine Model of High-Risk Keratoplasty (ARVO Abstract)... Mice in the treatment group systemically received integrin alpha 5 inhibiting molecules (JSM6427; 23 mg/kg/d) via subcutaneous osmotic pumps (Alzet® Pumps) for 14 days (n = 20)....

But, I suspect that some other slow release formulation is being referenced in the July 13, 2007 press release that you highlighted.

The slightly different wording in Jerini’s April 20, 2005 press release (see: http://www.bmp.com/homepage.nsf/(AllFrames)/2047 ) makes me wonder if an ocular implant is contemplated.

i.e.

Jerini AG presents positive Macular Degeneration data - Results Support Advancement of the Company’s Compound into Clinical Trials

Berlin, Germany, April 20, 2005

Jerini AG, a biopharmaceutical company focused on the discovery and development of peptide-derived (peptidomimetic) and small molecule therapeutics, presents positive data from its age-related macular degeneration (AMD) program at the IBC’s 2nd Annual Ocular Angiogenesis Conference on March 24, 2005 in Cambridge, MA and at the upcoming ARVO Conference in May in Fort Lauderdale, FL...... Jerini’s compound offers several potential advantages over current therapies in regard to efficacy, disease progression and patient convenience. "The initial assessment studies of our compound (JSM6427) have shown extremely positive efficacy in all predictive pre-clinical models. Our data also support the development of a slow release formulation. This would be a great advantage to patients because it could be administered conveniently every six months and would not require an injection into the eye. We have currently scheduled the initiation of Phase I clinical trials in the first-half of 2006," said Jochen Knolle, Chief Scientific Officer and Head of Research and Development at Jerini.